Pembrolizumab in PD-L1-positive advanced non-small cell lung carcinoma: A meta-analysis of survival benefits and immune-related toxicity events patterns: Original scientific article. ADMET and DMPK, [S. l.], v. 13, n. 5, p. 2956, 2025. DOI: 10.5599/admet.2956. Disponível em: https://pub.iapchem.org/ojs/index.php/admet/article/view/2956. Acesso em: 17 nov. 2025.